Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m 2 per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to expl...
Gespeichert in:
| Veröffentlicht in: | Annals of hematology 2020-11, Vol.99 (11), p.2539-2546 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2546 |
|---|---|
| container_issue | 11 |
| container_start_page | 2539 |
| container_title | Annals of hematology |
| container_volume | 99 |
| creator | Zhang, Kaiji Lian, Ying Guan, Xiaohong Hu, Qian Lei, Lihua Tao, Li He, Dong Lin, Juan Hou, Zheng Ren, Lirong Liu, Xiaoxiao Ren, Qian Pan, Lin Fei, Xiaoli Xiong, Mei Wen, Shunzhu Cao, Jinzhu |
| description | Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m
2
per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to explore the clinical application of a low dose of decitabine for treating MDS. In this retrospective study, we examined the effects of a very-low-dose decitabine schedule for treating MDS. A total of 13 patients diagnosed with de novo MDS received a schedule of intravenous decitabine administration at 6 mg/m
2
per day for 7 days, repeated every 4 weeks. The complete response rate was 30.8%, and the overall response rate was 69.2%. In patients with complete remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L during complete remission (CR) was 15 days. In patients with remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L was 10.5 days. The 1-year survival rate was 72.7% and the median survival was 28.0 months. In summary, we demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS. |
| doi_str_mv | 10.1007/s00277-020-04268-z |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443885884</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443885884</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-b72f0b746e9b505ccc9e2c20f204c3cc6cd721016d8cfe42bc35ab8da1075f373</originalsourceid><addsrcrecordid>eNp9kUFv1DAQhS0EEkvhD3DykYthYjsbLzdUQUGq1AtwtZzJpOuSxMHjpUp_Bz8Y0-XMXGak995IT58Qrxt42wB07xhAd50CDQqs3jv18ETsGmu0gtbZp2IHB3NQbZ3n4gXzHUCjndU78fs75U1N6V4NiUkOhLGEPi4kS6ZQZlqKHFOWayix3izvYznKuBTKMw0xFFKyysd4e1Q58g85bzSlYeN1ClwiSt6WIaeZ3ssgM5WceCUs8RfJsIRp48gyjbIcYy5Ei8TAxC_FszFMTK_-7Qvx7dPHr5ef1fXN1ZfLD9cKjbZF9Z0eoe_sng59Cy0iHkijhlGDRYO4x6HTDTT7weFIVvdo2tC7ITTQtaPpzIV4c_675vTzRFz8HBlpmsJC6cReW2uca52z1arPVqwNONPo1xznkDffgP-LwJ8R-IrAPyLwDzVkziGu5uWWsr9Lp1xr8_9SfwASc48I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443885884</pqid></control><display><type>article</type><title>Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases</title><source>SpringerLink Journals</source><creator>Zhang, Kaiji ; Lian, Ying ; Guan, Xiaohong ; Hu, Qian ; Lei, Lihua ; Tao, Li ; He, Dong ; Lin, Juan ; Hou, Zheng ; Ren, Lirong ; Liu, Xiaoxiao ; Ren, Qian ; Pan, Lin ; Fei, Xiaoli ; Xiong, Mei ; Wen, Shunzhu ; Cao, Jinzhu</creator><creatorcontrib>Zhang, Kaiji ; Lian, Ying ; Guan, Xiaohong ; Hu, Qian ; Lei, Lihua ; Tao, Li ; He, Dong ; Lin, Juan ; Hou, Zheng ; Ren, Lirong ; Liu, Xiaoxiao ; Ren, Qian ; Pan, Lin ; Fei, Xiaoli ; Xiong, Mei ; Wen, Shunzhu ; Cao, Jinzhu</creatorcontrib><description>Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m
2
per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to explore the clinical application of a low dose of decitabine for treating MDS. In this retrospective study, we examined the effects of a very-low-dose decitabine schedule for treating MDS. A total of 13 patients diagnosed with de novo MDS received a schedule of intravenous decitabine administration at 6 mg/m
2
per day for 7 days, repeated every 4 weeks. The complete response rate was 30.8%, and the overall response rate was 69.2%. In patients with complete remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L during complete remission (CR) was 15 days. In patients with remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L was 10.5 days. The 1-year survival rate was 72.7% and the median survival was 28.0 months. In summary, we demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS.</description><identifier>ISSN: 0939-5555</identifier><identifier>EISSN: 1432-0584</identifier><identifier>DOI: 10.1007/s00277-020-04268-z</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Hematology ; Medicine ; Medicine & Public Health ; Oncology ; Original Article</subject><ispartof>Annals of hematology, 2020-11, Vol.99 (11), p.2539-2546</ispartof><rights>Springer-Verlag GmbH Germany, part of Springer Nature 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-b72f0b746e9b505ccc9e2c20f204c3cc6cd721016d8cfe42bc35ab8da1075f373</citedby><cites>FETCH-LOGICAL-c324t-b72f0b746e9b505ccc9e2c20f204c3cc6cd721016d8cfe42bc35ab8da1075f373</cites><orcidid>0000-0002-3579-9882</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00277-020-04268-z$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00277-020-04268-z$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids></links><search><creatorcontrib>Zhang, Kaiji</creatorcontrib><creatorcontrib>Lian, Ying</creatorcontrib><creatorcontrib>Guan, Xiaohong</creatorcontrib><creatorcontrib>Hu, Qian</creatorcontrib><creatorcontrib>Lei, Lihua</creatorcontrib><creatorcontrib>Tao, Li</creatorcontrib><creatorcontrib>He, Dong</creatorcontrib><creatorcontrib>Lin, Juan</creatorcontrib><creatorcontrib>Hou, Zheng</creatorcontrib><creatorcontrib>Ren, Lirong</creatorcontrib><creatorcontrib>Liu, Xiaoxiao</creatorcontrib><creatorcontrib>Ren, Qian</creatorcontrib><creatorcontrib>Pan, Lin</creatorcontrib><creatorcontrib>Fei, Xiaoli</creatorcontrib><creatorcontrib>Xiong, Mei</creatorcontrib><creatorcontrib>Wen, Shunzhu</creatorcontrib><creatorcontrib>Cao, Jinzhu</creatorcontrib><title>Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases</title><title>Annals of hematology</title><addtitle>Ann Hematol</addtitle><description>Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m
2
per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to explore the clinical application of a low dose of decitabine for treating MDS. In this retrospective study, we examined the effects of a very-low-dose decitabine schedule for treating MDS. A total of 13 patients diagnosed with de novo MDS received a schedule of intravenous decitabine administration at 6 mg/m
2
per day for 7 days, repeated every 4 weeks. The complete response rate was 30.8%, and the overall response rate was 69.2%. In patients with complete remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L during complete remission (CR) was 15 days. In patients with remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L was 10.5 days. The 1-year survival rate was 72.7% and the median survival was 28.0 months. In summary, we demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS.</description><subject>Hematology</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><issn>0939-5555</issn><issn>1432-0584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kUFv1DAQhS0EEkvhD3DykYthYjsbLzdUQUGq1AtwtZzJpOuSxMHjpUp_Bz8Y0-XMXGak995IT58Qrxt42wB07xhAd50CDQqs3jv18ETsGmu0gtbZp2IHB3NQbZ3n4gXzHUCjndU78fs75U1N6V4NiUkOhLGEPi4kS6ZQZlqKHFOWayix3izvYznKuBTKMw0xFFKyysd4e1Q58g85bzSlYeN1ClwiSt6WIaeZ3ssgM5WceCUs8RfJsIRp48gyjbIcYy5Ei8TAxC_FszFMTK_-7Qvx7dPHr5ef1fXN1ZfLD9cKjbZF9Z0eoe_sng59Cy0iHkijhlGDRYO4x6HTDTT7weFIVvdo2tC7ITTQtaPpzIV4c_675vTzRFz8HBlpmsJC6cReW2uca52z1arPVqwNONPo1xznkDffgP-LwJ8R-IrAPyLwDzVkziGu5uWWsr9Lp1xr8_9SfwASc48I</recordid><startdate>20201101</startdate><enddate>20201101</enddate><creator>Zhang, Kaiji</creator><creator>Lian, Ying</creator><creator>Guan, Xiaohong</creator><creator>Hu, Qian</creator><creator>Lei, Lihua</creator><creator>Tao, Li</creator><creator>He, Dong</creator><creator>Lin, Juan</creator><creator>Hou, Zheng</creator><creator>Ren, Lirong</creator><creator>Liu, Xiaoxiao</creator><creator>Ren, Qian</creator><creator>Pan, Lin</creator><creator>Fei, Xiaoli</creator><creator>Xiong, Mei</creator><creator>Wen, Shunzhu</creator><creator>Cao, Jinzhu</creator><general>Springer Berlin Heidelberg</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3579-9882</orcidid></search><sort><creationdate>20201101</creationdate><title>Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases</title><author>Zhang, Kaiji ; Lian, Ying ; Guan, Xiaohong ; Hu, Qian ; Lei, Lihua ; Tao, Li ; He, Dong ; Lin, Juan ; Hou, Zheng ; Ren, Lirong ; Liu, Xiaoxiao ; Ren, Qian ; Pan, Lin ; Fei, Xiaoli ; Xiong, Mei ; Wen, Shunzhu ; Cao, Jinzhu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-b72f0b746e9b505ccc9e2c20f204c3cc6cd721016d8cfe42bc35ab8da1075f373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Hematology</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhang, Kaiji</creatorcontrib><creatorcontrib>Lian, Ying</creatorcontrib><creatorcontrib>Guan, Xiaohong</creatorcontrib><creatorcontrib>Hu, Qian</creatorcontrib><creatorcontrib>Lei, Lihua</creatorcontrib><creatorcontrib>Tao, Li</creatorcontrib><creatorcontrib>He, Dong</creatorcontrib><creatorcontrib>Lin, Juan</creatorcontrib><creatorcontrib>Hou, Zheng</creatorcontrib><creatorcontrib>Ren, Lirong</creatorcontrib><creatorcontrib>Liu, Xiaoxiao</creatorcontrib><creatorcontrib>Ren, Qian</creatorcontrib><creatorcontrib>Pan, Lin</creatorcontrib><creatorcontrib>Fei, Xiaoli</creatorcontrib><creatorcontrib>Xiong, Mei</creatorcontrib><creatorcontrib>Wen, Shunzhu</creatorcontrib><creatorcontrib>Cao, Jinzhu</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhang, Kaiji</au><au>Lian, Ying</au><au>Guan, Xiaohong</au><au>Hu, Qian</au><au>Lei, Lihua</au><au>Tao, Li</au><au>He, Dong</au><au>Lin, Juan</au><au>Hou, Zheng</au><au>Ren, Lirong</au><au>Liu, Xiaoxiao</au><au>Ren, Qian</au><au>Pan, Lin</au><au>Fei, Xiaoli</au><au>Xiong, Mei</au><au>Wen, Shunzhu</au><au>Cao, Jinzhu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases</atitle><jtitle>Annals of hematology</jtitle><stitle>Ann Hematol</stitle><date>2020-11-01</date><risdate>2020</risdate><volume>99</volume><issue>11</issue><spage>2539</spage><epage>2546</epage><pages>2539-2546</pages><issn>0939-5555</issn><eissn>1432-0584</eissn><abstract>Decitabine is a hypomethylating drug that is used to treat myelodysplastic syndrome (MDS) at a recommended dose and schedule (20 mg/m
2
per day, for 5 consecutive days). However, due to its relatively high incidence of side effects and its effects on neoplastic cells, many studies have begun to explore the clinical application of a low dose of decitabine for treating MDS. In this retrospective study, we examined the effects of a very-low-dose decitabine schedule for treating MDS. A total of 13 patients diagnosed with de novo MDS received a schedule of intravenous decitabine administration at 6 mg/m
2
per day for 7 days, repeated every 4 weeks. The complete response rate was 30.8%, and the overall response rate was 69.2%. In patients with complete remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L during complete remission (CR) was 15 days. In patients with remission, the median time to granulocyte recovery greater than 0.5 × 10
9
/L was 10.5 days. The 1-year survival rate was 72.7% and the median survival was 28.0 months. In summary, we demonstrated that a very-low-dose decitabine schedule has an appreciable response and survival rate, as well as appreciable tolerance and medical compliance for treating MDS.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><doi>10.1007/s00277-020-04268-z</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3579-9882</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0939-5555 |
| ispartof | Annals of hematology, 2020-11, Vol.99 (11), p.2539-2546 |
| issn | 0939-5555 1432-0584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2443885884 |
| source | SpringerLink Journals |
| subjects | Hematology Medicine Medicine & Public Health Oncology Original Article |
| title | Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-16T07%3A34%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Very-low-dose%20decitabine%20treatment%20for%20patients%20with%20intermediate-%20or%20high-risk%20myelodysplastic%20syndrome:%20a%20retrospective%20analysis%20of%20thirteen%20cases&rft.jtitle=Annals%20of%20hematology&rft.au=Zhang,%20Kaiji&rft.date=2020-11-01&rft.volume=99&rft.issue=11&rft.spage=2539&rft.epage=2546&rft.pages=2539-2546&rft.issn=0939-5555&rft.eissn=1432-0584&rft_id=info:doi/10.1007/s00277-020-04268-z&rft_dat=%3Cproquest_cross%3E2443885884%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443885884&rft_id=info:pmid/&rfr_iscdi=true |